Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial

<strong>Background:</strong> In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting antiretroviral therapy (ART). This group also has the greatest risk of morbidity and mortality associated with immun...

Bibliografiset tiedot
Päätekijät:	Kityo, C, Szubert, A, Siika, A, Heydermann, R, Bwakura-Dangarembizi, M, Lugemwa, A, Mwaringa, S, Griffiths, A, Nkanya, I, Kabahenda, S, Wachira, S, Musoro, G, Rajapakse, C, Etyang, T, Abach, J, Spyer, M, Wavamunno, P, Nyondo-Mipanda, L, Chidziva, E, Nathoo, K, Klein, N, Hakim, J, Gibb, D, Walker, A, Pett, S
Aineistotyyppi:	Journal article
Julkaistu:	Public Library of Science 2018

Samankaltaisia teoksia

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
Tekijä: Cissy Kityo, et al.
Julkaistu: (2018-12-01)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
Tekijä: Hakim, J, et al.
Julkaistu: (2017)

Late presentation with HIV in Africa: phenotypes, risk and risk stratification in the REALITY trial
Tekijä: Siika, A, et al.
Julkaistu: (2018)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
Tekijä: Hakim, J, et al.
Julkaistu: (2017)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
Tekijä: Hakim, J, et al.
Julkaistu: (2017)

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
Tekijä: Mallewa, J, et al.
Julkaistu: (2018)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
Tekijä: Szubert, A, et al.
Julkaistu: (2015)

Raltegravir in treatment naïve patients
Tekijä: Cossarini F, et al.
Julkaistu: (2009-11-01)

Raltegravir monohydrate
Tekijä: H. S. Yathirajan, et al.
Julkaistu: (2013-12-01)

HIV resistance to raltegravir
Tekijä: Clavel François
Julkaistu: (2009-11-01)

Raltegravir use in special populations
Tekijä: Johnson Margaret
Julkaistu: (2009-11-01)

Drug-drug interactions with raltegravir
Tekijä: Burger David M
Julkaistu: (2009-11-01)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
Tekijä: Bwakura-Dangarembizi, M, et al.
Julkaistu: (2015)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
Tekijä: Alexander J Szubert, et al.
Julkaistu: (2017-11-01)

Ethical and legal constraints to children’s participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial
Tekijä: Bwakura-Dangarembizi Mutsa, et al.
Julkaistu: (2012-07-01)

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe
Tekijä: Prendergast, A, et al.
Julkaistu: (2019)

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa
Tekijä: Riitho, V, et al.
Julkaistu: (2024)

Raltegravir in the management of HIV-infected patients
Tekijä: Hans-J&uuml;rgen Stellbrink
Julkaistu: (2008-12-01)

Raltegravir: first in class HIV integrase inhibitor
Tekijä: Zelalem Temesgen, et al.
Julkaistu: (2008-06-01)

Raltegravir: molecular basis of its mechanism of action
Tekijä: Mouscadet Jean-François, et al.
Julkaistu: (2009-11-01)

Role of raltegravir in the management of HIV-1 infection
Tekijä: Okeke NL, et al.
Julkaistu: (2011-07-01)

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
Tekijä: Aleksey Viktorovich Kravchenko, et al.
Julkaistu: (2010-11-01)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial
Tekijä: Szubert, A, et al.
Julkaistu: (2017)

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
Tekijä: Bwakura-Dangarembizi, M, et al.
Julkaistu: (2014)

Allergic hypersensitivity to antiretroviral drugs: etravirine, raltegravir and darunavir
Tekijä: Manuel Anastacio Sánchez-Olivas, et al.
Julkaistu: (2015-04-01)

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
Tekijä: Goubau Patrick, et al.
Julkaistu: (2010-11-01)

Dissolution Enhancement of Raltegravir by Hot Melt Extrusion Technique
Tekijä: Ahmed S. Abdul Jabbar
Julkaistu: (2018-06-01)

Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
Tekijä: Aylin Yilmaz, et al.
Julkaistu: (2009-09-01)

Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo
Tekijä: Xue Zhang, et al.
Julkaistu: (2019-08-01)

Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy
Tekijä: Prendergast, A, et al.
Julkaistu: (2016)

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa
Tekijä: Victor Riitho, et al.
Julkaistu: (2024-06-01)

Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents
Tekijä: Nuttall J, et al.
Julkaistu: (2013-08-01)

Drug-induced hypersensitivity syndrome after initiation of darunavir and raltegravir
Tekijä: Walter de Araujo Eyer-Silva, et al.

Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection
Tekijä: Lisa M Chirch, et al.
Julkaistu: (2010-04-01)

Rapid Reduction in HIV Viral Load in Late Pregnancy with Raltegravir
Tekijä: Agnes Cha PharmD, et al.
Julkaistu: (2013-09-01)

Long-term efficacy and safety of raltegravir in the management of HIV infection
Tekijä: Liedtke MD, et al.
Julkaistu: (2014-03-01)

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
Tekijä: Musoke, P, et al.
Julkaistu: (2015)

Optimal Use of Raltegravir (Isentress®) in the Treatment of HIV-Infected Adults – Canadian Consensus Guidelines
Tekijä: Anita Rachlis, et al.
Julkaistu: (2009-01-01)

Features of application of raltegravir in HIV-infected patients with different somatic pathologies
Tekijä: N. V. Sizova, et al.
Julkaistu: (2021-10-01)

Repurposing raltegravir for reducing inflammation and treating cancer: a bioinformatics analysis
Tekijä: Zahra Nikfarjam, et al.
Julkaistu: (2024-12-01)